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Abstract
Background: Interventions targeting multiple risk factors for cardiovascular disease (CVD), including poor diet and
physical inactivity, are more effective than interventions targeting a single risk factor. A motivational interviewing
(MI) intervention can provide modest dietary improvements and physical activity increases, while adding cognitive
behaviour therapy (CBT) skills may enhance the effects of MI. We designed a randomised controlled trial (RCT) to
examine whether specific behaviour change techniques integrating MI and CBT result in favourable changes in
weight and physical activity in those at high risk of CVD. A group and individual intervention will be compared to
usual care. A group intervention offers potential benefits from social support and may be more cost effective.
Methods/Design: Individuals aged between 40 and 74 years in 11 South London Clinical Commissioning Groups
who are at high risk of developing CVD (≥20%) in the next 10 years will be recruited. A sample of 1,704 participants
will be randomised to receive the enhanced MI intervention, delivered by trained healthy lifestyle facilitators
(HLFs), in group or individual formats, in 10 sessions (plus an introductory session) over one year, or usual care.
Randomisation will be conducted by King’s College London Clinical Trials Unit and researchers collecting outcome
data will be blinded to treatment allocation. At 12-month and 24-month follow-up assessments, primary outcomes
will be change in weight and physical activity (average steps per day). Secondary outcomes include changes in
low-density lipoprotein cholesterol and CVD risk score. Incidence of CVD events since baseline will be recorded. A
process evaluation will be conducted to evaluate factors which impact on delivery, adherence and outcome. An
economic evaluation will estimate relative cost-effectiveness of each type of intervention delivery.
Discussion: This RCT assesses the effectiveness of a healthy lifestyle intervention for people at high risk of CVD.
Benefits of the study include the ethnic and socioeconomic diversity of the study population and that, via social
support within the group setting and long-term follow-up period, the intervention offers the potential to support
maintenance of a healthy lifestyle.
Trial registration: This trial is registered with the ISRCTN registry (identifier: ISRCTN84864870, registered 15 May 2012).
Keywords: Cardiovascular disease, Physical activity, Diet, Accelerometer, Motivational interviewing, CBT, Primary care,
Health trainers
* Correspondence: khalida.2.ismail@kcl.ac.uk
1Department of Psychological Medicine, Institute of Psychiatry, King’s College
London, 10 Cutcombe Road, London SE5 9RJ, UK
Full list of author information is available at the end of the article
TRIALS
© 2015 Bayley et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Bayley et al. Trials  (2015) 16:112 
DOI 10.1186/s13063-015-0593-5
Background
Epidemiology of cardiovascular disease and its risk
factors
Cardiovascular disease (CVD) is the most common
cause of death (and premature death), morbidity and
disability in middle-aged and older people both in the
United Kingdom and in other developed countries [1].
However, CVD is highly preventable as many of the
major determinants of CVD are modifiable, including
cigarette smoking, a diet high in saturated fat, high
serum cholesterol, obesity, sedentary lifestyle, hyperten-
sion and diabetes [1-5]. The risk of CVD varies mark-
edly between ethnic groups, with a higher rate of
ischaemic heart disease in South Asians and a higher
rate of cerebrovascular disease in Africans amongst
those living in England and Wales [6].
Although CVD remains the most common cause of
death in developed nations, mortality rates have been
falling. Between 1981 and 2000, CVD mortality in the
United Kingdom fell by 62% in men and by 45% in
women [7]. Cohort studies [8] and prediction models [7]
suggested that a fall in the prevalence of cigarette smok-
ing, a decline in population blood pressure levels and
changes in cholesterol levels were important contribu-
tors. Population-wide changes in modifiable risk factors
can bring about substantial benefits and further changes
in blood lipids, particularly non-high density lipoprotein
(HDL) cholesterol, could be achieved through population-
wide dietary changes [8]. However, limited changes in
physical activity and rising levels of obesity have limited
the decline in CVD mortality [8]. Further efforts are
therefore needed to bring about positive changes, par-
ticularly in diet, obesity and physical activity.
The evidence for dietary interventions
Systematic reviews of randomised controlled trials
(RCTs) of generic dietary advice interventions for redu-
cing CVD risk in the primary prevention setting have
generally found small beneficial effects on mean total
and low-density lipoprotein (LDL) cholesterol levels, as
well as small reductions in blood pressure, but HDL
cholesterol and triglyceride levels remain unchanged
[9]. Most studies were conducted in the United States,
with a short average duration of 10 months. Compared
with usual care, dietary instruction interventions
produce modest weight losses and these diminish over
time [10].
The evidence for increasing physical activity
Physical inactivity increases overall mortality and the risk
of many diseases, including CVD and diabetes [11]. The
Department of Health advises adults to perform at least
30 minutes of at least moderate intensity physical activity
on five or more days per week, in at least 10 minute bouts,
for optimum health benefits [11]. Walking is the most
common form of physical activity in adults and is pro-
moted as a near perfect exercise as it has the lowest risk
of harm, and is now public health policy in the United
Kingdom [12,13].
However, the proportion of those achieving these rec-
ommendations is low, particularly when objective mea-
sures are used to assess physical activity. In England,
39% of men and 29% of women self-report achieving the
recommended physical activity levels, but objective as-
sessment of physical activity using accelerometers in a
sub-sample of the Health Survey for England found that
only 5% of men and 4% of women aged 35 to 64 years
achieved the recommended levels [14]. A Cochrane re-
view of 17 RCTs reported moderate positive short-term
increases in physical activity following health interven-
tions, either in a group or individual format, but findings
were limited since most studies used self-report mea-
sures in motivated volunteers [15]. There is mounting
evidence that the use of pedometers as a method of aid-
ing self-monitoring can increase physical activity and
improve health in the short term [16]. Social support
and cognitive behaviour therapy (CBT) strategies, rather
than health education alone, are now recommended in
older adults [17].
The evidence for motivational interviewing
The Cochrane Heart Group systematic review of
multiple risk factor interventions observed that tech-
niques based on instruction and information such as
workshops, lectures, provision of written material, as-
signments, shopping tours and cooking sessions were
associated with small improvements in lipid levels and
reductions in blood pressure, especially when embedded
in a theoretical framework related to behaviour change
[18]. Motivational interviewing (MI) is a common ap-
proach to behavior change in health care defined as a
collaborative, goal-oriented style of communication
with particular emphasis on the language of change
[19]. It is designed to strengthen personal motivation
for, and commitment to, a specific goal by eliciting and
exploring the person’s own reasons for change within an
atmosphere of acceptance and compassion [20]. An MI
intervention moves through the following processes: en-
gaging, focusing, evoking and planning. The core skills
of MI can by summarised by the acronym OARS: Open
question, Affirmations, Reflections and Summaries. The
appeal of MI is that it is brief, can be delivered by a
range of health providers and has a competency frame-
work. Systematic reviews and meta-analyses have con-
sistently shown that MI techniques have a moderate
effect on diet and exercise (effect sizes (d) of 0.53 stand-
ard deviations in four RCTs) [21]. In another meta-
analysis of MI interventions, significant effects were
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seen for weight reduction and for reducing cholesterol,
although the number of trials was few [22].
The effects of MI can be short-lived. We found that
four sessions of MI alone was not associated with im-
proved glycaemic control in people with type 1 diabetes,
but four sessions of MI followed by eight sessions of
CBT was associated with improved glycaemic control
(compared to usual care [23]). These effects disappeared
after 12 months [24]. During the process evaluation, it
was found that MI helped people to become more ready
to change their behaviours, but the change was less
likely to be implemented without additional support
[25]. However, the evidence for enhancing MI with CBT
is not consistent as the landmark Combined Pharmaco-
therapies and Behavioral Interventions for Alcohol De-
pendence study (COMBINE) did not demonstrate
increased abstinence in those receiving the psychological
intervention [26].
A taxonomy of behaviour change techniques
The epidemic of modifiable risk factors for CVD and the
limitations of current models of lifestyle interventions,
particularly their short-term effects, is leading to a
search for more sophisticated and targeted behavioural
interventions [27]. For instance, systematic reviews have
shown that the components of behavioural interventions
that appeared to be most effective in improving diet and
physical activity were based on self-regulatory behav-
iours such as goal setting, self-monitoring, giving feed-
back, utilising social support and MI. Interventions
based on a psychological theory (such as the theory of
planned behaviour [28]) were more effective, as were
those for high risk populations. There is less evidence to
support a case for any minimum threshold of intensity,
mode of delivery, intervention provider and setting
[18,27,29]. Strategies to prevent relapses and to increase
the maintenance of healthier lifestyles over longer pe-
riods remain poorly understood and understudied.
Evaluating interventions in the context of a taxonomy of
behaviour change techniques and an intervention map
offer a framework that is easier to teach, test, replicate
and translate [28-30].
Cardiovascular risk
The NHS Health Check programme is part of the De-
partment of Health’s long-term vision for the future of
public health in England [31]. In offering checks to all
those aged between 40 and 74 years without a known
diagnosis of CVD the programme aims to prevent heart
disease, stroke, diabetes and kidney disease and to re-
duce health inequalities. The risk assessment includes
collection of demographic data, family history, smoking
status, cholesterol, blood pressure and a diabetes filter
using computerised risk engines such as QRISK,
QRISK2 or the Framingham. An individualised manage-
ment plan is then given according to the risk assessment
to support lifestyle changes such as referral to smoking
cessation services, exercise prescriptions, lifestyle advice
and signposting to local resources. However, the
programme has attracted criticism due to the lack of an
up-to-date evidence base for the implementation of
Health Checks, and Clinical Commissioning Groups
(CCGs) lacking the resources to implement them [32].
Therefore, a wider evidence base is required to substan-
tiate the benefits of a Health Check programme. In this
trial, we aim to evaluate whether MI integrated with
CBT can effectively prevent development of disease in
those at high risk of CVD.
The role of health trainers and healthy lifestyle facilitators
We propose to structure our intervention, which is
based on MI integrated with CBT, around health
trainers. The deployment of health trainers, or healthy
lifestyle facilitators (HLFs), into the public health work-
force has the potential to address health inequalities; an
important issue within the multi-ethnic and variably de-
prived South London boroughs. They are usually drawn
from the local community they serve and are trained in
a variety of settings with national accreditation. Their
role includes identifying clients from hard-to-reach dis-
advantaged groups, working one-to-one to assess life-
style and wellbeing, identifying problem areas, setting
goals, supporting behaviour change and reviewing their
clients’ progress [33]. The potential for a HLF to deliver
more sophisticated interventions, either in an individual
or a group format, has yet to be studied [34].
Summary
The potential benefits at the population level of modify-
ing diets, reducing weight, reducing cholesterol levels
and increasing physical activity are considerable. How-
ever, identifying the most effective intervention targeting
lifestyle changes remains a challenge for researchers and
policy makers. MI is an intervention that has broad ap-
peal for its collaborative patient-centred style, brevity,
evidence base and deliverability. The effects of MI could
be enhanced by embedding it into a taxonomy of spe-
cific health behaviour change techniques, such as setting
personal goals, offering physical tools to self-monitor
(such as pedometers) and offering guidance and feed-
back. The relative effectiveness of a group versus an in-
dividual intervention remains uncertain, but the former
offers ‘automatic’ social support and may be more cost-
effective.
We propose to compare the effectiveness of 10 pre-
specified behaviour change techniques (integrating MI
with CBT and underpinned by the theory of planned be-
haviour and social cognitive theory) in reducing weight
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and increasing physical activity in those at high risk of
CVD over 24 months in two formats, group or individ-
ual, with usual care.
Methods/Design
Design
This is a three-arm, parallel, multicentre RCT for people
identified as at high risk for CVD. The three arms are
usual care, usual care and enhanced MI in a group for-
mat and usual care and enhanced MI in an individual
format. As participants of the group arm, but not the
other two arms, are clustered within groups we have a
partially clustered (or nested) design. Simple randomisa-
tion will be used, with GP practice included as a random
factor in the model, and emphasis being on more prac-
tices and fewer patients per practice. The trial is funded
by the National Institute for Health Research - Health
Technology Assessment Programme (NIHR-HTA) and
has been registered with the International Standard Ran-
domised Controlled Trial Number (ISRCTN) registry
(identifier: ISRCTN84864870). The study flow chart in




Enhanced MI, delivered in a group or individual format,
is more effective than usual care in reducing weight and
increasing physical activity (average number of steps per
day assessed via accelerometry) 24 months later.
Secondary hypotheses
1. Enhanced MI delivered in a group format is more
effective than in an individual format in reducing
weight and increasing physical activity (average
number of steps per day assessed via accelerometry)
24 months later.
2. Enhanced MI, delivered in a group or individual
format, is more effective than usual care in reducing
LDL cholesterol, reducing CVD risk score and
increasing moderate to vigorous physical activity
Figure 1 Study flow chart showing progression through trial. A 20% dropout rate is assumed.
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((MVPA) amount of at least moderate physical
activity in longer than 10 minute bouts) 24 months
later.
3. Enhanced MI, delivered in a group or individual
format, is more cost-effective than usual care, in
terms of quality-adjusted life years (QALYs) gained
over the 24 month follow-up period.
Secondary objectives: process evaluation
Mediational analysis
We will conduct a mediational analysis to examine
whether changes in behavioural and psychological fac-
tors such as dietary intake, health beliefs, depressive
symptoms and self-efficacy mediate the association be-
tween the intervention and outcomes.
Effect modification and subgroup analyses
Subgroup analyses will be used to examine whether the
association between the intervention and the outcomes
are modified by sociodemographic, lifestyle and psycho-
logical factors measured at baseline, such as age, gender,
ethnicity, family history of CVD, smoking status, alcohol
intake, index of deprivation and depressive symptoms.
The power for identifying significant effect modification
will be limited.
Fidelity
A fidelity analysis (using mixed methods) will be con-
ducted to assess whether the enhanced MI intervention
is delivered according to the manual and to compare
whether the level of competencies between the HLFs is
associated with variations in outcomes using rating
scales and thematic contents analysis of sessions.
Patient and therapist experience analysis
Using qualitative methods, we will describe the per-
ceived expectations, benefits, strengths and limitations
of the intervention from the patient and therapist
perspective.
Setting
The study is set in 11 South London CCGs (Bexley,
Bromley, Croydon, Greenwich, Kingston, Lambeth, Lew-
isham, Richmond and Twickenham, Southwark, Sutton
and Merton and Wandsworth) that are linked to each
other by the South London Health Innovation and Edu-
cation Cluster (SLHIEC), and inherent in this infrastruc-
ture is an efficient method for recruitment. South
London has additional advantages: the population is
nearly three million residents; nearly a quarter of the
population is either African, Caribbean or South Asian;
it spans the range of population densities, urbanisation
and socioeconomic profiling; the development of a
Health Innovation Network (HIN) in South London will
allow rapid dissemination of research findings and it will
be cheaper than a multicentre study across the United
Kingdom, as research resources can be shared across ad-
jacent CCGs during periods of varying workload. GP
practices with list sizes greater than 5,000 patients will
be invited to take part, representing approximately 60%
of all practices within the SLHIEC. To recruit patients
from every practice in the SLHIEC is not cost-beneficial,
as smaller practices will have fewer patients to recruit
from. A limitation is that the South London sample may
not be representative of the rest of the United Kingdom,
and not address the north and south regional health in-
equalities. However, there are many pockets of health in-
equalities within South London that mirror the rest of
the United Kingdom, and we are well-placed in being in
a geographical setting that has a significant proportion
of Africans, Caribbeans and South Asians to address eth-
nicity in the design.
Target population
The sampling frame will be GP practices with list sizes
greater than 5,000 patients. The case definition includes
adults aged between 40 and 74 years who screen as posi-
tive for high CVD risk, and not known to have CVD or
to be on the diabetes, kidney, atrial fibrillation or stroke
register. Following screening via the patient records
database, the GP will invite those who are potentially eli-
gible to participate in the study.
Informed consent is gained from all participants prior
to undergoing screening in order to validate their eligi-
bility to participate. High CVD risk will be calculated
using QRISK2 (QResearch, Nottingham, UK), a validated
predictive tool for identifying those at a 20% or higher
chance of having a fatal or non-fatal cardiovascular
event over the next 10 years [35]. The measures required
for the calculation of QRISK2 score are age (years),
smoking status, self-assigned ethnicity, systolic blood
pressure, ratio of total serum cholesterol to HDL choles-
terol, body mass index (BMI), family history of coronary
heart disease in first degree relative, Townsend
deprivation score, treated hypertension and diagnosis of
rheumatoid arthritis.
Criteria for including and excluding patients
The inclusion criteria are: fluent in conversational Eng-
lish, permanent residents and planning to stay in the
United Kingdom for at least three quarters of the year
and at high cardiovascular risk according to GP records
(QRISK2 score ≥20%).
The exclusion criteria are: established CVD (including
congenital heart disease, angina, myocardial infarction,
coronary revascularisation procedures, peripheral artery
disease, coronary artery bypass graft or angioplasty); hav-
ing a pacemaker; on a register for diabetes, kidney
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disease, atrial fibrillation or stroke (either ischemic or
haemorrhagic, including transient ischemic attacks);
chronic obstructive pulmonary disease; disabling neuro-
logical disorder; severe mental illness such as psychosis,
learning disability, dementia and cognitive impairment;
registered blind; housebound or resident in nursing
home; unable to move about independently or not am-
bulatory; more than three falls in past year; pregnancy;
advanced cancer; morbid obesity (BMI ≥50 kg/m2); and
current participation in a weight loss programme. When
in doubt we will seek the GP opinion and approval.
Sample size
The power calculation of our main outcome variables
are based on the findings of previous research [16,36].
We have selected a very conservative effect size of 0.25
expressed as the difference in units of pooled standard
deviations, which translates to an ability to detect a dif-
ference between two groups of 675 steps per day (phys-
ical activity), 1.25 kg weight and 0.25 umol/l total
cholesterol at 24 month follow-up. Our study is powered
to detect changes which may be modest at the individual
level, but would have an important impact if occurring
at the population level [37].
We took into account clustering effect within the group
intervention (intraclass correlation coefficient = 0.05) by
calculating the optimal sample size in presence of differen-
tial clustering effects [38]. A sample size of 1,420 partici-
pants in total are needed to detect these differences in our
primary hypotheses, and a two-tailed alpha of 0.025 to
take account of multiple comparisons of the contrasts ‘in-
dividual intervention versus control group’, ‘group inter-
vention versus control group’ and ‘group versus individual
intervention’. Assuming an approximate dropout rate of
20%, a total sample size of 1,704 (540 in group and 440 in
individual and usual care) is needed.
Baseline data
Sociodemographic data
Data on age, gender, self-report ethnicity, occupational
status, educational attainment, marital status, literacy
and family history of CVD will be collected.
Biomedical data
We will collect data on weight, height, BMI, waist circum-
ference, lipids and glycated haemoglobin (HbA1c). We are
not measuring fasting glucose as it is not essential to the
current diagnosis criteria for diabetes. Weight will be mea-
sured in light clothing, without shoes, on a Class 3 Tanita
SC240 weighing digital scale (Tanita, Tokyo, Japan) to
0.01 kg for weight and body fat composition. Height will
be measured to 0.1 cm using stadiometers (Tantita, Tokyo,
Japan) with the supported stretch stature method. Weight
and height measurements will be used to calculate BMI
(weight/height, kg/m2). Waist circumference will be mea-
sured horizontally halfway between the lowest rib and the
upper prominence of the pelvis using a non-extensible
steel tape against the bare abdomen. Blood pressure and
resting heart rate will be measured with digital Omron BP
monitors (Omron, Kyoto, Japan) using standardised pro-
cedures of the average of two readings taken one minute
apart while seated. The QRISK2 score will be the research
measure of CVD risk.
Lifestyle data
We will collect data on smoking status: if current how
many cigarettes per day, ex-smoker (for how many
years) and never smoked. We will collect and store
blood samples for later measurement of cotinine levels.
Alcohol intake will be measured using the Alcohol Use
Disorders Identification Test [39].
Physical activity will be measured objectively using the
ActiGraph GT3X accelerometer (ActiGraph, Florida,
United States), a tri-axial movement sensor which also re-
cords step counts. The ActiGraph instrument has been
validated and will collect data on number of steps taken
and physical activity from sedentary to very vigorous [40].
The researcher will explain to the participant how to wear
the accelerometer; on a belt over the hip for seven days,
from waking in the morning until going to bed at night,
and only removing for bathing. Participants are asked to
keep a log of activities, including sedentary ones, to assist
with the qualitative interpretation of the data. The output
from the accelerometer includes number of steps and time
spent doing physical activity using standard cut-off points
for sedentary, light, moderate, vigorous and very vigorous
physical activity. The researcher will ensure that, on the
participant returning the accelerometer, it has been worn
for at least 540 minutes on each of at least five days, and if
not the participant will be asked to wear the accelerometer
for another seven days. A measurement of physical activity
at moderate level or greater (MVPA) in longer than 10 mi-
nute bouts will be extracted from the data collected.
Dietary intake will also be assessed. A standardised
multiple-pass 24-hour dietary recall will be carried out as
it can be more objective and more reliable as a measure of
change in intervention studies. Researchers will be trained
to follow a standardised protocol, ask neutral probing
questions to encourage recall of food items, and taught
about different methods of food preparations and brands
in different cultures. Portion size will be assessed with
food photographs to estimate daily calorie intake [41,42].
Total and non-HDL cholesterol will be measured as a
proxy biomarker of change in dietary fat intake.
Psychological data
Health beliefs about diet, exercise and perceptions of
risk for developing CVD and related conditions will be
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measured by the Brief Illness Perception Questionnaire,
adapted for perception of risk [43]. Self-report physical
activity will be measured by the Global Physical Activity
Questionnaire (GPAQ) and International Physical Activ-
ity Questionnaire (IPAQ) [44]. Self-efficacy measures for
physical activity and dietary habits will be included as
psychological processes we are seeking to change during
the intervention [45]. Depressive symptoms will be mea-
sured using the nine-item Patient Health Questionnaire
[46], as depression is associated with worse outcomes in
CVD [47].
Randomisation and allocation concealment
Randomisation of participants will be conducted by the
data manager from an independent Clinical Trials Unit
(King's College London) using computer-generated ran-
domisation blocks with block sizes of 10. In each block,
10 subjects will be randomised to group, individual or
usual care in a 4:3:3 ratio. The unequal allocation ratio
ensures that the group arm will have approximately 33%
more patients, allowing the group sessions to run with a
sufficient number of participants. As this is a complex
intervention, it is not possible to conceal the allocation
to the participants or the HLFs. Assessors and techni-
cians will be blind to the allocation for the primary and
secondary outcomes. There is a small inevitable risk that
allocation will be revealed to the outcome assessors,
which will be minimised by requesting and reminding
participants not to reveal their allocation.
Planned interventions
Group one: usual care
GPs participating in the study will be expected to follow
their local Health Check pathway for those who have a
CVD risk score of ≥20%.
Group two: usual care and enhanced motivational
interviewing in a group format
Theoretical framework The intervention will be based
on the theory of planned behaviour [28] for initiation of
behaviour change, which states that in order to change
behaviour, people need to form an intention. Intention
formation is influenced by three constructs: expected
value or positive attitude (people see the value in making
the change); subjective norm (significant others and
peers also value the change) and self-efficacy (people be-
lieve they are capable of making the change).
Our intervention will tap into all three constructs
using principles and techniques from MI [19], CBT [48]
and social cognitive theory [49] (Figure 2). MI will be
used to support participants in forming healthy intentions.
MI is a collaborative conversation style for strengthening
a person’s own motivation, belief and commitment to
change. Hobbis and Sutton highlight the gap between
translating intention into action and illustrate how CBT
can be applied to bridge this gap [48]. For this interven-
tion, techniques from CBT will be used to support the
transition from intention to action, and action to mainten-
ance [50]. Identifying and challenging unhelpful thoughts
or thinking styles can promote more positive emotions
and behaviours [51]. For example, ‘When I get breathless
after some exercise (bodily sensation) this means I am go-
ing to damage my heart (incorrect cognition)’ or ‘I have
eaten one doughnut (behaviour) - I might as well eat the
whole bag (all or nothing cognition)’.
Social cognitive theory emphasises the importance of
significant others in shaping people’s behaviours. The
theory of planned behaviour also highlights this aspect
through the ‘subjective norm’ construct. In our interven-
tion, social networks from the participant’s own life and/
or group members (in the group arm) will be actively
utilised to provide practical and emotional support and
opportunities for modeling health behaviours during all
phases of the intervention.
Intervention development We will conduct a scoping
study to identify manuals published in English in the last
five years to improve diet and/or physical activity in the
peer-reviewed and grey literature. The aim is to map the
quality, contents and cultural diversity of these manuals
to inform the content of our intervention. The clinical
psychologist will devise the intervention based on this
synthesis and on our expertise in developing lifestyle in-
terventions. We will use an iterative process to draft the
manual and refine it over two to three cycles. There will
be three manual outputs from the trial:
1. A training manual: This will describe the teaching
methods, structure and content of the training
programme used to train the HLFs.
2. An intervention curriculum: This will describe the
outline of each intervention session including key
learning points, interactive activities and action
planning.
3. A participant workbook: This will include key
learning points from each session, action planning
worksheets, case studies and a self-monitoring diary
for each participant. The participants will also
receive a pedometer with guidance on how to use
this effectively and access to online, DVD and paper
resources around CVD risk.
The programme will consist of 10 sessions, plus an
introductory session, spread quarterly over 12 months.
The outline of each session is described in Table 1. Each
participant allocated to a treatment arm will have a ses-
sion 0 as an introduction to the intervention, to receive
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their intervention packs and to become familiar with the
HLF. The intensive phase consists of six weekly sessions
at the beginning of the first quarter. The first three ses-
sions focus on physical activity and the second three ses-
sions focus on diet. The maintenance phase consists of
four sessions delivered at three, six, nine and twelve
months. Those randomised to the group arm are encour-
aged to use the peer learning and peer support environ-
ment to facilitate change during the intensive phase and
maintenance phase. Each group has typically 10 to 11 par-
ticipants and sessions last 120 minutes. The intervention
will be delivered in local venues such as community halls
and health centres. In between sessions and during the
follow-up period, participants will be encouraged to com-
municate with each other (in the group arm) and the HLF
(both individual and group). Novel methods and teaching
aides are used to supplement the delivery of behaviour
change techniques such as visual aids of food labels and/
or cue cards, exercise demonstrations, video and/or audio
material of patient testimonials, activity-based learning
around meal planning and text and/or email reminders.
For ease of translation, the key components of the
programme have been defined according to Abraham and
Michie’s behaviour change technique taxonomy [30]:
1. Provide information on consequences,
2. Prompt intention formation,
3. Prompt barrier identification,
4. Prompt specific goal setting,
5. Prompt review of behavioural goals,
6. Prompt self-monitoring of behavior,
7. Teach to use prompts or cues,
8. Agree on behavioural contract,
9. Use follow-up prompts,
10. Plan social support or social change,
11. Relapse prevention and
12. Motivational interviewing.
Training the healthy lifestyle facilitators The HLFs
are at NHS Band 3 level, employed by King's College
Hospital and seconded as appropriate to the CCG. The
training programme lasts eight weeks. The teaching is a
combination of didactic learning, role plays and feed-
back, group exercises, reading and case study discussion.
The HLFs will use rating scales for self-monitoring of
skill progression during role plays. The HLF is deemed
ready to administer the intervention when they have
achieved a specific competency level [52]. We will adapt
existing competency frameworks for behaviour change
techniques to this study [53-55]. HLFs are expected to
offer sessions between 8 am and 9 pm, enabling flexibil-
ity for participants who are in full-time work or have
carer roles. Cultural and religious awareness is built in.
Regular supervision during the intervention will be pro-
vided by the clinical psychologist.
Group three: usual care and enhanced motivational
interviewing in an individual format
This will have the same components as group two but
the components are delivered individually. There will be
no opportunity, expectation or guidance for participants
to form groups with each other in between sessions.
Figure 2 Intervention map of MOVE-IT for cardiovascular disease risk scores of more than 20%.
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Sessions will last 40 minutes. We have kept the number
of sessions the same and reduced the duration of each
session to approximately match for attention in the two
groups.
Measurement of outcomes
Interim and outcome assessments are collected by research
workers using standardised approaches. All laboratory ana-
lyses will be carried out by technicians blind to allocation.
The main outcome will be treatment differences between
the arms at 24 months, with an interim assessment at 12
months.
Primary outcomes
The primary outcomes are change in weight (kg) and phys-
ical activity (average number of steps per day) between arms.
The same methods of assessment as at baseline will be used.
Secondary outcomes
Change in LDL cholesterol and CVD risk score will be
assessed. The QRISK2 measurement of CVD risk will be
sensitive to changes in weight, cholesterol, blood pres-
sure, diabetes status (HbA1c) and smoking status. The
number of fatal and non-fatal CVD events and hospital
admissions will be recorded via the Hospital Episodes
Statistics database [56].
Table 1 Proposed programme of sessions
Session number Content of session
Intensive phase:
Session 0 Focus: Introduce the intervention
Examples of delivery: structure of the programme, ice breaker, rapport building with HLF, give out pedometers
and baseline measures.
Session 1: physical activity Focus: Increasing routine activity
(Week 1) Examples of delivery: Elicit views regarding walking more and sitting less and instruction on use of pedometer.
Support individual goal setting.
Session 2: physical activity Focus: Increasing non routine activity
(Week 2) Examples of delivery: Elicit views on recommended activity levels and reflect on previously enjoyed exercise and
its benefits. Provide information/demonstration/leaflets regarding local exercise options. Support individual goal setting.
Session 3: physical activity Focus: To maintain physical activity changes
(Week 3) Examples of delivery: Elicit views regarding lapse versus relapse using case studies. Discuss lapse triggers
and strategies to manage them. Support individual relapse prevention plans (including implementation intentions).
Session 4: diet Focus: Increasing health food choices
(Week 4) Examples of delivery: Elicit views on healthy eating principles. Interactive games regarding healthy snacks.
Support individual goal setting.
Session 5: diet Focus: Decreasing unhealthy food choices
(Week 5) Elicit views on foods to avoid in excess. Interactive games regarding food labelling and high fat and salt foods.
Support individual goal setting.
Session 6: diet Focus: To maintain dietary changes
(Week 6) Examples of delivery: Elicit views regarding lapse versus relapse using case studies. Discuss lapse triggers and
strategies to manage them. Support individual relapse prevention plans (including implementation intentions).
Maintenance phase:
Session 7 Focus: Review progress and problem-solve setbacks
(3 months) Examples of delivery: Highlight positive changes in review session, discuss setbacks and potential ways forward.
Support individual relapse prevention plans.
Session 8 Focus: Review progress and problem-solve setbacks
(6 months) Examples of delivery: Highlight positive changes in review session, discuss setbacks and potential ways forward.
Support individual relapse prevention plans.
Session 9 Focus: Review progress and problem-solve setbacks
(9 months) Examples of delivery: Highlight positive changes in review session, discuss setbacks and potential ways forward.
Support individual relapse prevention plans.
Session 10 Focus: Review progress and problem-solve setbacks
(12 months) Examples of delivery: Highlight positive changes in review session, discuss setbacks and potential ways forward.
Support individual relapse prevention plans.
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A secondary physical activity outcome will be the
amount of at least moderate physical activity (MVPA) in
longer than 10 minute bouts, assessed using the acceler-
ometer output. Changes in dietary habits will be mea-
sured via analysis of dietary recall data. Health beliefs
and depression at 12 and 24 months will be assessed as
measures of mediating processes.
The main perspective for the economic evaluation will
be that of the health care system. The EuroQol-5D will
be used to generate QALYs for use in the economic ana-
lyses [57]. Intervention costs will be calculated, taking
into account staff time involved in being trained and de-
livering interventions, overhead costs and sessions pro-
vided. For the group intervention the costs will be
apportioned over attendees. Other service use will be
measured at baseline, 12 month and 24 month follow-up
assessments using an adapted Client Service Receipt In-
ventory (CSRI) [58]. Costs will be calculated by combin-
ing service use data with information on unit costs [59].
Secondary analyses will take into account costs for other
agencies and will include lost employment costs.
Statistical analysis plan
A description of the sample will be presented using means
and their standard deviations or counts (proportions).
Baseline characteristics of those who were eligible but de-
cline to participate with those who consent to participate
and those who dropped out of follow up will be compared
with participants who complete the study. Analysis and
reporting will be in line with the Consolidated Standards of
Reporting Trials (CONSORT) guidelines [60], with pri-
mary analyses being on an intention-to-treat basis. The dif-
ferences in treatment effect between the three arms at 12
and 24 months of this partially nested design will be ana-
lysed using mixed-effects models with pre-randomisation
values as a covariate [61]. In the linear mixed-model treat-
ment arm, time (as a categorical variable with two levels -
12 and 24 months), the interaction between treatment
group and time, borough, ethnicity and the baseline values
of the outcome variable are the fixed part of the model.
The random parts of the models are GP practice (patients
are nested in practices) and therapy group. To account for
the partially nested design of the therapy group (only pa-
tients within the group therapy are clustered within the
same group) an approach which matches the non-parallel
data structure will be used [61]. The dependency of the re-
peated observations of the same subjects at 12 and 24
months and the covariance between the residuals within
the lowest level (patients) is to be correlated by using an
unstructured covariance pattern model. For the final model
the group difference estimates and associated confidence
intervals will be reported for 12 (for secondary analyses)
and 24 months after randomisation.
The large sample size should ensure that all possible
confounding variables are equally distributed between
treatment arms. However, in a sensitivity analysis we ex-
tend the analyses model of the primary analysis by in-
cluding baseline variables with substantial imbalance,
thought to be important in determining outcome, in the
model. The potential baseline variables are age, gender,
index of deprivation, education, and marital and smok-
ing status.
The described analyses approach provides valid infer-
ences under the assumption that the missing data mech-
anism can be ignored (missing at random). Sensitivity of
results to missing data will be further assessed by includ-
ing covariates predictive of missingness in the analyses
model, using multiple imputation [62] and exploring the
effect of relaxing the missing at random assumption to
allow for informative dropout, that is letting missingness
also depend on the unobserved value [63].
Health care costs will be compared between the three
groups. Given that the data are likely to be skewed, we
will use bootstrapping methods to estimate 95% confi-
dence intervals around the mean cost differences. Costs
including social care and lost employment will also be
compared between the groups. The lost employment
costs will be based on days lost from work and average
wage rates. However, there is a danger of double-
counting between QALYs and lost employment, and
therefore the cost-effectiveness analyses will be based on
the health service perspective. QALYs will be calculated
from the EuroQol-5D administered at baseline, 12
months and 24 months. Area under the curve methods
will allow us to calculate the QALY gain over the entire
follow-up period. If costs are higher for one group com-
pared to another and QALY gains are greater, we will
then construct an incremental cost-effectiveness ratio to
show the cost per extra QALY gained. There will be un-
certainty around cost and QALY estimates and this will
be explored using cost-effectiveness planes generated
from 1,000 bootstrapped resamples of the data for each
of the three comparisons. Finally, we will generate cost-
effectiveness acceptability curves, using the net-benefit
approach and bootstrapping, to indicate the probability
that any of the three approaches is the most cost-
effective for different values placed on a QALY gain. The
range of values used will be £0 to 100,000. This includes
the threshold that is used by the National Institute for
Health and Care Excellence of £20,000 to 30,000. Sensi-
tivity analyses will be carried out around key costs, par-
ticularly those for the interventions themselves.
Qualitative analysis
The overall aim is to identify and describe factors and
processes that affect the delivery, receipt and outcome of
the study to aid the interpretation and translation of the
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observed findings. Process data will be analysed before
outcome data wherever possible to reduce bias in inter-
pretation. The main themes will be reach, quality (fidel-
ity) and processes of change.
Reach
The extent to which the intervention reached out to eli-
gible participants will be assessed by comparing the rea-
sons given by GPs as to why they agree or decline to
participate. We will also assess participation and attri-
tion biases; some patients who have declined to partici-
pate in the RCT may be willing to give written informed
consent to collect baseline data. We will also invite pa-
tients who complete less than 50% of sessions to attend
a focus group to give feedback on the programme.
Quality (fidelity)
We will measure adherence and competence. Adherence
is the extent to which the therapist applies the tech-
niques prescribed in the manual and avoids those pro-
scribed. For MI we will use the MI Treatment Integrity
(MITI), which counts the number of MI techniques used
[52], and for an overall assessment of competency we
will adapt emerging competency frameworks [53-55].
There is no consensus as to the number and order of
sessions that should be analysed [25]. Considering the
potential massive volume of material we will audiotape
sections of 25% of all sessions, selected randomly.
Processes of change
We will scan copies of self-monitoring worksheets to
measure adherence to the intervention. Supervision
checklists and interviews with health trainers will be used
to assess which behavior change techniques are popular,
why and for which lifestyle behaviour. We will administer
a detailed process questionnaire at 15 months that
requires all randomised participants to discuss, in open-
ended and standardised structured questionnaires, which
techniques they had found most useful, their appraisal of
the techniques and their level of satisfaction with the
interventions of their allocated arms. We will include the
usual care arm in order to assess the similarity and differ-
ences with the intervention as there may be some overlap.
Ethical issues
The trial has been reviewed by the Dulwich Ethics Com-
mittee and has been approved (reference: 12/LO/0917).
The Trial Steering Committee (TSC) will provide overall
trial supervision supported by the Data Monitoring and
Ethics Committee (DMEC). Professor Steve Iliffe, Professor
of Primary Care of the Elderly, University College London
is the chairperson for the TSC and Professor Helen Weiss,
Head of International Epidemiology, London School of
Hygiene and Tropical Medicine, is the chairperson for the
DMEC. The main ethical consideration is to ensure that
the risk of harm to participants is minimised and that they
are fully informed of any risks. We will take into account
literacy and cultural sensitivities in obtaining informed
consent. Other ethical considerations are ensuring that re-
cruitment and informed consent are handled in such a way
that potential participants are not put under pressure to
take part, and that confidentiality is preserved. All partici-
pant data will be stored using a unique study identifier and
electronic data will be password protected.
In general, regular physical activity is associated with
improved health outcomes and this outweighs the risk
of sedentary lifestyles. However, a sudden increase in
vigorous physical activity in otherwise sedentary individ-
uals is associated with a higher risk of myocardial infarc-
tion and of musculoskeletal injuries, which may be
pertinent as we are intervening in a group that is at high
risk for CVD. However, one of the components of be-
haviour change techniques is to deliver the message that
physical activity should be increased in a graded manner
rather than suddenly. We will be discouraging excessive
and/or sudden changes to lifestyles. Weight loss could
worsen frailty by accelerating the usual age-related loss
of muscle that leads to sarcopenia, but combining weight
loss with increased physical activity can actually amelior-
ate frailty [64]. Importantly, our intervention is based on
healthier diets and gradual and sustainable weight loss
as opposed to commercial weight loss programmes. We
consider risks to be small and minimal due to the exclu-
sion of subjects with existing CVD.
Adverse events
An adverse event, which may be classed as serious, is
defined as any untoward occurrence during the course
of the study which should be reported to the Research
Ethics Committee (REC) and TSC within an agreed
timeframe. A suspected unexpected serious adverse
event (SUSAR) is defined as an untoward occurrence
that is related to the intervention and is unexpected.
Participants will have the opportunity to report adverse
events at 12-month and 24-month study appointments
with the researcher, and participants receiving the inter-
vention will be able to report adverse events at any time
during the intervention period to the HLF. All serious
adverse events and laboratory values will be reviewed by
the principal investigator and another co-investigator,
and the principal investigator will be responsible for de-
termining causality and reporting any adverse events re-
lated to the study to the REC using the National
Research Ethics Service guidance.
Obtaining informed consent
GP staff will conduct the searches using our guidance and
invite potential participants to give permission for the
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research workers to contact them. Research workers will
invite potential participants to meet them in the surgery,
and they will be given verbal and written information
about the study and at least one week to think about par-
ticipating. We will invite patients who are eligible but de-
cline participation to give informed consent for the
collection of baseline data to assess the generalizability of
our findings.
Withdrawal and stopping rules
Participants will be free to withdraw from the study at
any time. If the participant withdraws from the interven-
tion, they will be asked if they are happy to attend
follow-up study appointments and for data to be col-
lected. If they withdraw from the study without consent
to follow-up, no further data will be collected.
There are no formal stopping rules. This is due to the
fact that the intervention does not ask participants to do
anything more than follow usual GP advice regarding
diet and physical activity. However, the principal investi-
gator will evaluate the causality of any adverse events
and advise withdrawal if necessary.
Time period for retention of trial documentation
A copy of patient consent forms will be kept for 12
months after the study has ended. Personal data that are
identified by patient name or address will be destroyed
three years after the study has ended. Other trial records
will be archived for seven years after the trial ends be-
fore being destroyed.
Discussion
This study will compare the effectiveness of enhanced
MI interventions, in a group and individual format, with
usual care for reducing weight and increasing physical
activity in 40 to 74-year-olds with a high risk (≥20%) of
developing CVD in the next 10 years. The study will
take place across 11 CCGs in South London and will as-
sess changes at 24 months, with an interim assessment
at 12 months. The relative effectiveness of group and in-
dividual interventions will be assessed; it is predicted
that participants in the group intervention will benefit
from social support and that this approach will be more
cost-effective than the individual format.
The benefits of the study setting include the infrastruc-
ture for dissemination of research findings (through the
HIN), and that a significant proportion of the South
London population is African, Caribbean or South Asian.
A limitation is that health inequalities between the north
and south of the United Kingdom will not be addressed.
However, health inequalities within South London mirror
the rest of the United Kingdom, and South London is
well-placed in being a geographical setting with a multi-
ethnic population across a variably deprived setting,
allowing ethnicity and deprivation to be addressed in the
study design. Changes in NHS organisation during the
course of the study also present challenges, including the
transfer of public health responsibilities from the NHS to
local government and the change from primary care trusts
to CCGs. Poor uptake of the NHS Health Check
programme has also prompted changes to recruitment pro-
cedures. Variably outdated data on patient records systems
may lead to inaccurate estimate of CVD risk and, therefore,
large numbers of ineligible participants consented.
The intervention offers the advantage of potentially ac-
tive ingredients to support maintenance, such as social
support within the group intervention and a long-term
follow-up period. One challenge is in avoiding selection
bias in the study design and ensuring the intervention tar-
gets those most at need, as participants who respond to
the invite to take part in the study may already be moti-
vated. However, as the participants will have screened at
high risk of CVD there is cause for treatment.
During the study, ensuring blinding to treatment allo-
cation may also be an issue. It will not be possible for
the participant or HLF to be blind to treatment alloca-
tion due to the nature of the intervention. The re-
searcher will be blind to the treatment allocation and
will remind the participant about this when carrying out
outcome measurements. When unblinding does occur
this will be recorded. Objective physical assessments and
accelerometer data, as well as a standardised procedure
for self-report measures, will limit any researcher bias
possible during outcome assessment.
Trial status
Study appointments started in June 2013 and the intended
end date is February 2017. Recruitment of GP surgeries
and participants is taking place between June 2013 and
January 2015; longer than initially anticipated. Due to poor
uptake of the NHS Health Check programme the size of
the population to be screened needed to be increased.
QRISK2 scores based on patient records database screen-
ing need to be confirmed by inviting patients for formal
screening. This has led to an almost doubling of the popu-
lation that needs to be consented, as approximately 40 to
50% of those consented have been ineligible. Therefore,
the recruitment target has been increased to 3,000 partici-
pants in order to randomise the 1,704 required. The final
report will be prepared for June 2017.
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